Page 399 - شرور شركات الأدوية

‫ﻣﻼﺣﻈﺎت‬

‫ إﺧﻔﺎء ﺑﻴﺎﻧﺎت اﻟﺘﺠﺎ ِرب‬:‫اﻟﻔﺼﻞ اﻷول‬

(1) Bourgeois FT, Murthy S, Mandl KD. Outcome Reporting Among
Drug Trials Registered in ClinicalTrials.gov. Annals of Internal Medicine.
2010;153(3):158–66.

(2) Bero L, Oostvogel F, Bacchetti P, Lee K. Factors Associated with
Findings of Published Trials of Drug-Drug Comparisons: Why Some Statins
Appear More Efficacious than Others. PLoS Med. 2007 Jun 5;4(6):e184.

(3) Kelly RE Jr, Cohen LJ, Semple RJ, Bialer P, Lau A, Bodenheimer A, et
al. Relationship between drug company funding and outcomes of clinical
psychiatric research. Psychol Med. 2006 Nov;36(11):1647–56.

(4) Bekelman JE, Li Y, Gross CP. Scope and impact of financial
conflicts of interest in biomedical research: a systematic review. JAMA
2003;289:454–65. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceu-
tical industry sponsorship and research outcome and quality: systematic
review. BMJ 2003;326:1167–70.

(5) Sismondo S. Pharmaceutical company funding and its conse-
quences: A qualitative systematic review. Contemporary Clinical Trials.
2008 Mar;29(2):109–13.